SCID-X1 gene therapy (AVAX)

N/A

Report date: 2024/09/10 15:36:50

Base Information

Drug NameSCID-X1 gene therapy (AVAX)
Drug Alias NameSCID gene therapy - AVAXSCID-XI gene therapy
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionLymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsImmunologic Deficiency Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNecker-Enfants Malades Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNecker-Enfants Malades HospitalAvax Technologies Inc
Active IndicationsN/A
Inactive IndicationsImmunologic Deficiency Syndromes

Other Information

ATC CodeN/A
Related LinksN/A